연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1641. Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Kim JW1, Min CK2, Mun YC3, Park Y4, Kim BS4, Nam SH5, Koh Y6, Kwon JH7, Choe PG8, Park WB9, Kim I10.
J Clin Virol. 2015 Dec;73:64-9. doi: 10.1016/j.jcv.2015.10.018. Epub 2015 Oct 24.
Link
1640. Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer.
Lee YG1,2, Lee E1, Kim I1, Lee KW3, Kim TM1, Lee SH1, Kim DW1, Heo DS1.
Cancer Res Treat. 2015 Oct;47(4):670-5. doi: 10.4143/crt.2014.045. Epub 2015 Jan 2.
Link
1639. Total costs and clinical outcome of hematopoietic stem cell transplantation in adults with leukemia: comparison between reduced-intensity and myeloablative conditioning.
Suh KJ1, Kim I, Lim J, Ha H, Park S, Koh Y, Yoon SS, Park S.
Clin Transplant. 2015 Feb;29(2):124-33. doi: 10.1111/ctr.12492. Epub 2014 Dec 20.
Link
1638. Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Suh KJ1, Keam B2, Kim M1, Park YS1, Kim TM3, Jeon YK4, Kim DW3, Chung DH4, Kim YW1, Heo DS3.
Clin Lung Cancer. 2015 Nov 30. pii: S1525-7304(15)00276-4. doi: 10.1016/j.cllc.2015.11.012. [Epub ahead of print]
Link
1637. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Kim R1, Hahn S2,3, Shin J1, Ock CY1, Kim M1, Keam B1,4, Kim TM1,4, Kim DW1,4, Heo DS1,4.
Cancer Res Treat. 2015 Nov 17. doi: 10.4143/crt.2015.359. [Epub ahead of print]
Link
1636. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho KM1,2, Keam B1,3, Kim TM1,3, Lee SH1,3, Kim DW1,3, Heo DS1,3.
Korean J Intern Med. 2015 Nov;30(6):891-8. doi: 10.3904/kjim.2015.30.6.891. Epub 2015 Oct 30.
Link
1635. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
Keam B1, Lee SJ, Kim TM, Paeng JC, Lee SH, Kim DW, Jeon YK, Chung DH, Kang KW, Chung JK, Heo DS.
J Thorac Oncol. 2015 Aug;10(8):1189-94. doi: 10.1097/JTO.0000000000000569.
Link
1634. VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma.
Park S1, Nam SJ2, Keam B1, Kim TM1, Jeon YK2, Lee SH1, Hah JH3, Kwon TK3, Kim DW1, Sung MW3, Heo DS1, Bang YJ1
Cancer Res Treat. 2015 Jul 14. doi: 10.4143/crt.2015.093. [Epub ahead of print]
Link
1633. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Keam B1,2, Kim SB3, Shin SH4, Cho BC5, Lee KW6, Kim MK7, Yun HJ8, Lee SH1,2, Yoon DH3, Bang YJ1,2.
Cancer. 2015 Aug 1;121(15):2612-7. doi: 10.1002/cncr.29401. Epub 2015 Apr 22.
Link
1632. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Keam B1, Kim S2, Ahn YO2, Kim TM1, Lee SH1, Kim DW1, Heo DS3.
Anticancer Res. 2015 Jan;35(1):175-82.
Link